Candesartan
2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 2541.
Listing
- Schedules
- Schedule 3
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
Counted through the register's ingredient index, which does not reach every record.
3 more registered products name Candesartan in their active ingredient
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Atacand | Atacand | 8 mg, 16 mg, 32 mg | Equity Pharmaceutical (Pty) Ltd | 3 registrations | |
| Candesartan Ran | Candesartan ran | 8, 16 | Ranbaxy Pharmaceutical (Pty) Ltd | 2 registrations | |
| Candagen Cancelled | Candagen | 8, 16 | Ranbaxy Pharmaceutical (Pty) Ltd | 2 registrations | |
| Mylacand | Mylacand | 8 mg, 16 mg | Viatris South Africa (Pty) Ltd | 2 registrations | |
| Raphex Cancelled | Raphex | 8 mg, 16 mg, 32 mg | Astrazeneca Pharmaceuticals (Pty) Ltd | 3 registrations | |
| Abecard | Abecard | 8, 16, 32 | Forrester Pharma (Pty) Ltd | 3 registrations | |
| Zidesart | Zidesart | 8, 16 | Zydus Healthcare (Pty) Ltd | 2 registrations | |
| Candesartan Zydus | Candesartan zydus | 8, 16 | Zydus Healthcare (Pty) Ltd | 2 registrations | |
| Artewin Cancelled | Artewin | 8 mg, 16 mg, 32 mg | Zentiva South Africa (Pty) Ltd | 3 registrations | |
| Ranepres | Ranepres | 8 MG, 16 MG, 32 MG | Macleods Pharmaceuticals SA (Pty) Ltd | 3 registrations | |
| Candesartan Austell Cancelled | Candesartan austell | 8 mg, 16 MG, 32 MG | Austell Pharmaceuticals (Pty) Ltd | 3 registrations | |
| Atacand Plus | Atacand plus | 16/12,5 mg, 32/12,5 mg, 32/25 mg | Equity Pharmaceutical (Pty) Ltd | 3 registrations |
Show the other 8 registered products
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Candesartan Plus Htz Oethmaan | Candesartan plus htz oethmaan | Not stated | Oethmaan Biosims (Pty) Ltd | 440554 | |
| Candepres Plus | Candepres plus | 12.5 mg | Sandoz South Africa (Pty) Ltd | 440555 | |
| Mylacand Plus | Mylacand plus | 16/12,5 mg | Viatris South Africa (Pty) Ltd | 450394 | |
| Raphex Plus Cancelled | Raphex plus | 16/12,5 mg | Astrazeneca Pharmaceuticals (Pty) Ltd | 450803 | |
| Abecard Co | Abecard co | 16/12,5 | Forrester Pharma (Pty) Ltd | 460230 | |
| Canuretic Cancelled | Canuretic | 16/12,5 mg, | Austell Pharmaceuticals (Pty) Ltd | 490054 | S3 |
| Arbtens Plus | Arbtens plus | Not stated | Aurogen South Africa (Pty) Ltd | 490302 | |
| Desar Plus | Desar plus | Not stated | Aurogen South Africa (Pty) Ltd | 4903030 |
Regulatory status
Where S3 sits on the scale
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Candesartan
S3: Candesartan
Consolidated Schedules 06 July 2026, line 3278
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.